Topic: Schering Ag

Dendreon Corporation (NASDAQ: DNDN) is supposed to be the king of prostate cancer with its PROVENGE treatment. Unfortunately, PROVENGE sales ran...

Dividend payouts are starting to taper off this week, as earnings season starts to slow. Not counting microcap names, a total of 26 firms increased...

Drug-maker Schering-Plough Corporation's (NYSE:SGP) shares have not been kind to long-term shareholders over the past five years. They're up a...

Merck & Co. (MRK) has had temporary supply shortages of certain women's health products in recent months as a result of the integration of...

Pharmaceutical and chemicals company Bayer AG (BAYN. XE) Monday issued a cautious outlook for 2011, as it expects strong generic drug competition ...

The headlines following Pfizer's (PFE) earnings touted research and development cuts and a big stock buyback. So much for growth from a broad...

Peter DiBattiste spent years as an interventional cardiologist clearing out heart patients' arteries. JNJ - news - people ), he is helping lead the testing of a powerful new blood thinner in late-stage tests in heart patients at J&J and Bayer (nyse: Results from a mid-stage study presented at a meeting of cardiologists showed the drug, rivaroxaban, slashed heart attacks and strokes by 31% when taken with aspirin and also, in some patients, Plavix, an anti-clotting drug from Bristol-Myers Squibb (nyse: Cell fragments called platelets clump together; Plavix and prasugrel block these. Next ...

Merck & Co. (MRK) is a leading global drugmaker, producing a wide range of prescription drugs in many therapeutic classes in the U.S. and abroad. In early November 2009, MRK acquired rival drugmaker Schering-Plough (SGP) for about $41 billion in cash and stock. The stock is down 10% since the start of the year despite executing well on integrating Schering - Plough and moving efficiently to gain cost savings from merger. MRK is selling for approximately 11 times this year's consensus earnings and 9.5 times next year's projected earnings. Given its growth prospects, improving pipeline, cost reduction efforts, and solid dividend yield; we believe Merck is undervalued.

Bayer Schering Pharma, a unit of the German chemicals group Bayer, has been hit by a lawsuit over a pregnancy test that allegedly caused birth defects, Der Spiegel reported Saturday.The lawsuit was brought by a 34-year-old Bavarian man who claims that ...

Dianabol, Anabol, Danabol DS and many other names are all the same Anabolic Steroid with the active ingredient being Methandienone or Methandrostenolone which are the same. This is 1 of the most popular if not the most popular oral steroid around today ...